Search research articles
Contact Us
Filters
Showing results (81-90 of 136) with videos related to
Page
of 14
Sort By:
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
Gerald S Falchook, James Reeves, Sunil Gandhi, et al.
Targeted Oncology
|
November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
Erika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
Cell Reports
|
January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
Filip Janku, David S Hong, Siqing Fu, et al.
The Lancet. Oncology
|
April 2, 2026
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
Melissa L Johnson, Manish R Patel, Gerald S Falchook, et al.
Investigational New Drugs
|
April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
Gerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Cancer
|
March 7, 2023
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors
Filip Janku, Milind M Javle, Shiraj Sen, et al.
Nature Medicine
|
January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Cancer
|
October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers
Filip Janku, Divya Sakamuri, Shumei Kato, et al.
Molecular Cancer Therapeutics
|
July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Jennifer J Wheler, Filip Janku, Aung Naing, et al.
Molecular Cancer Therapeutics
|
October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
Prasanth Ganesan, Filip Janku, Aung Naing, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 136) with videos related to
Sort By:
Page
of 14
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
Gerald S Falchook, James Reeves, Sunil Gandhi, et al.
Targeted Oncology
|
November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
Erika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
Cell Reports
|
January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
Filip Janku, David S Hong, Siqing Fu, et al.
The Lancet. Oncology
|
April 2, 2026
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
Melissa L Johnson, Manish R Patel, Gerald S Falchook, et al.
Investigational New Drugs
|
April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
Gerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Cancer
|
March 7, 2023
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors
Filip Janku, Milind M Javle, Shiraj Sen, et al.
Nature Medicine
|
January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Cancer
|
October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers
Filip Janku, Divya Sakamuri, Shumei Kato, et al.
Molecular Cancer Therapeutics
|
July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Jennifer J Wheler, Filip Janku, Aung Naing, et al.
Molecular Cancer Therapeutics
|
October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
Prasanth Ganesan, Filip Janku, Aung Naing, et al.
Page
of 14